Compare Abbott Laboratories (ABT) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Annaly Capital Management, Inc. — how do they compare? Abbott Laboratories trades at $109.48 (market cap $187.95B), while Annaly Capital Management, Inc. trades at $23.15 (market cap $17.44B). The key difference: Abbott Laboratories is far larger — about 10.8× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays the higher dividend (12.96%). Which is the better fit depends on your goals.
| ABT | NLY | |
|---|---|---|
Market Cap | $187.95B | $17.44B |
Sector | Health | Financials |
52-Week High | $136.62 | $24.40 |
52-Week Low | $82.57 | $20.21 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | 12.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
NLY trades at $22.91, down 0.56% today, with strong technical momentum showing a bullish moving average signal. The stock demonstrates robust fundamentals with a P/E of 5.59, ROE of 20.66%, and consistent earnings beats in recent quarters. Recent Q2 2026 results exceeded expectations with $0.79 EPS versus $0.75 estimate, supported by growing net interest income and dividend coverage improvements.
Analyst consensus remains positive with a $24.50 price target and 57% buy ratings, though investors should monitor interest rate sensitivity given the REIT's mortgage-focused business model. The 13%+ dividend yield provides income appeal, but funding costs and mortgage market volatility present ongoing risks to book value stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
